Which has better valuation & earnings, CLRB or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Biomea Fusion N/A N/A -$61.80M -$0.68 N/A

Is CLRB or BMEA more profitable?

Biomea Fusion's return on equity of -265.37% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Biomea Fusion N/A -265.37% -103.96%

Does the media refer more to CLRB or BMEA?

In the previous week, Cellectar Biosciences had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Cellectar Biosciences and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Cellectar Biosciences' score of 0.48 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LFVN or CLRB?

In the previous week, Lifevantage and Lifevantage both had 3 articles in the media. Lifevantage's average media sentiment score of 0.55 beat Cellectar Biosciences' score of 0.48 indicating that Lifevantage is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer CLRB or VRCA?

In the previous week, Cellectar Biosciences had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Cellectar Biosciences' score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, PMN or CLRB?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is PMN or CLRB more profitable?

Promis Neurosciences' return on equity of -237.99% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Promis Neurosciences N/A -237.99% -151.04% Cellectar Biosciences N/A -349.24% -153.18%

Does the media refer more to PMN or CLRB?

In the previous week, Cellectar Biosciences had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Cellectar Biosciences' score of 0.48 indicating that Promis Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FTLF or CLRB?

In the previous week, FitLife Brands and FitLife Brands both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Cellectar Biosciences' score of 0.48 indicating that FitLife Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FitLife Brands 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cellectar Biosciences (CLRB) Competitors

$2.72 +0.12 (+4.42%)

As of 01:55 PM Eastern

Compare

CLRB vs. BMEA, LFVN, VRCA, PMN, and FTLF

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include Biomea Fusion (BMEA), Lifevantage (LFVN), Verrica Pharmaceuticals (VRCA), Promis Neurosciences (PMN), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry.

How does Cellectar Biosciences compare to Biomea Fusion?

Cellectar Biosciences (NASDAQ:CLRB) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

In the previous week, Cellectar Biosciences had 1 more articles in the media than Biomea Fusion. MarketBeat recorded 3 mentions for Cellectar Biosciences and 2 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 0.62 beat Cellectar Biosciences' score of 0.48 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its stock price is 131% less volatile than the broader market.

Biomea Fusion's return on equity of -265.37% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Biomea Fusion	N/A	-265.37%	-103.96%

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cellectar Biosciences currently has a consensus target price of $11.00, indicating a potential upside of 311.99%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 522.71%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biomea Fusion is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Summary

Biomea Fusion beats Cellectar Biosciences on 9 of the 13 factors compared between the two stocks.

How does Cellectar Biosciences compare to Lifevantage?

Lifevantage (NASDAQ:LFVN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Lifevantage has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Lifevantage has a net margin of 2.94% compared to Cellectar Biosciences' net margin of 0.00%. Lifevantage's return on equity of 23.89% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifevantage	2.94%	23.89%	12.47%
Cellectar Biosciences	N/A	-349.24%	-153.18%

35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 22.0% of Lifevantage shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lifevantage currently has a consensus target price of $5.00, suggesting a potential downside of 49.37%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 311.99%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cellectar Biosciences is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lifevantage has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifevantage	$195.32M	0.64	$9.81M	$0.45	21.95
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

In the previous week, Lifevantage and Lifevantage both had 3 articles in the media. Lifevantage's average media sentiment score of 0.55 beat Cellectar Biosciences' score of 0.48 indicating that Lifevantage is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lifevantage beats Cellectar Biosciences on 11 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Cellectar Biosciences (NASDAQ:CLRB) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.63 beat Cellectar Biosciences' score of 0.48 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Cellectar Biosciences' return on equity of -349.24% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 311.99%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 141.18%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has higher revenue and earnings than Cellectar Biosciences. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Verrica Pharmaceuticals	$35.58M	2.90	-$17.89M	-$1.03	N/A

Cellectar Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Verrica Pharmaceuticals beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Promis Neurosciences?

Promis Neurosciences (NASDAQ:PMN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

In the previous week, Cellectar Biosciences had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.63 beat Cellectar Biosciences' score of 0.48 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Promis Neurosciences is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

50.1% of Promis Neurosciences shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 1.5% of Promis Neurosciences shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Promis Neurosciences' return on equity of -237.99% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Promis Neurosciences	N/A	-237.99%	-151.04%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Promis Neurosciences has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Promis Neurosciences currently has a consensus target price of $26.50, suggesting a potential upside of 170.35%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 311.99%. Given Cellectar Biosciences' higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Cellectar Biosciences beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

2.3% of FitLife Brands shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 61.4% of FitLife Brands shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

FitLife Brands has a net margin of 6.64% compared to Cellectar Biosciences' net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Cellectar Biosciences	N/A	-349.24%	-153.18%

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 113.82%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 311.99%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

FitLife Brands has a beta of 0.02, indicating that its share price is 98% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

FitLife Brands has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.16	$6.33M	$0.60	16.76
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

In the previous week, FitLife Brands and FitLife Brands both had 3 articles in the media. FitLife Brands' average media sentiment score of 0.87 beat Cellectar Biosciences' score of 0.48 indicating that FitLife Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FitLife Brands	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

FitLife Brands beats Cellectar Biosciences on 9 of the 14 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.33M	$8.21B	$6.43B	$12.45B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-0.40	15.68	23.85	24.37
Price / Sales	N/A	7.10	522.03	117.40
Price / Cash	N/A	17.10	41.27	57.13
Price / Book	1.41	3.64	10.04	6.75
Net Income	-$21.79M	$224.05M	$3.56B	$337.03M
7 Day Performance	-14.97%	0.41%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	-80.72%	2.77%	28.88%	34.01%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	3.7688 of 5 stars	$2.72 +4.4%	$11.00 +305.2%	-68.8%	$21.70M	N/A	N/A	10
BMEA Biomea Fusion	2.0348 of 5 stars	$1.42 +1.8%	$8.29 +485.6%	-47.8%	$99.77M	N/A	N/A	50	Gap Up
LFVN Lifevantage	2.9778 of 5 stars	$8.47 -10.1%	$5.00 -41.0%	-35.3%	$99.29M	$228.53M	23.07	260	Ex-Dividend High Trading Volume
VRCA Verrica Pharmaceuticals	2.7899 of 5 stars	$5.89 -0.3%	$14.50 +146.4%	+10.5%	$98.95M	$37.16M	N/A	40
PMN Promis Neurosciences	2.9794 of 5 stars	$10.14 -2.6%	$26.50 +161.5%	-21.2%	$96.94M	N/A	N/A	5	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BMEA, LFVN, VRCA, PMN, and FTLF

How does Cellectar Biosciences compare to Biomea Fusion?

Summary

How does Cellectar Biosciences compare to Lifevantage?

Summary

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to Promis Neurosciences?

Summary

How does Cellectar Biosciences compare to FitLife Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. BMEA, LFVN, VRCA, PMN, and FTLF

How does Cellectar Biosciences compare to Biomea Fusion?

Does the media refer more to CLRB or BMEA?

Which has more volatility and risk, CLRB or BMEA?

Is CLRB or BMEA more profitable?

Do institutionals & insiders have more ownership in CLRB or BMEA?

Do analysts prefer CLRB or BMEA?

Which has better valuation & earnings, CLRB or BMEA?

Summary

How does Cellectar Biosciences compare to Lifevantage?

Which has more risk and volatility, LFVN or CLRB?

Is LFVN or CLRB more profitable?

Do institutionals & insiders hold more shares of LFVN or CLRB?

Do analysts recommend LFVN or CLRB?

Which has stronger valuation and earnings, LFVN or CLRB?

Does the media refer more to LFVN or CLRB?

Summary

How does Cellectar Biosciences compare to Verrica Pharmaceuticals?

Does the media prefer CLRB or VRCA?

Is CLRB or VRCA more profitable?

Do analysts rate CLRB or VRCA?

Which has stronger earnings and valuation, CLRB or VRCA?

Which has more volatility and risk, CLRB or VRCA?

Do insiders & institutionals hold more shares of CLRB or VRCA?

Summary

How does Cellectar Biosciences compare to Promis Neurosciences?

Does the media refer more to PMN or CLRB?

Which has preferable valuation & earnings, PMN or CLRB?

Do institutionals and insiders hold more shares of PMN or CLRB?

Is PMN or CLRB more profitable?

Which has more risk & volatility, PMN or CLRB?

Do analysts prefer PMN or CLRB?

Summary

How does Cellectar Biosciences compare to FitLife Brands?

Do insiders & institutionals hold more shares of FTLF or CLRB?

Is FTLF or CLRB more profitable?

Do analysts recommend FTLF or CLRB?

Which has more risk & volatility, FTLF or CLRB?

Which has better valuation and earnings, FTLF or CLRB?

Does the media favor FTLF or CLRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools